Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 28, 2017

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Slow Dose Titration Group of Subcutaneous Treprostinil

subcutaneous treprostinil

DRUG

Rapid Dose Titration Group of Subcutaneous Treprostinil

subcutaneous treprostinil

Trial Locations (10)

100020

Beijing Chao-Yang Hospital, Beijing

100029

Beijing Anzhen Hospital, Capital Medical University, Beijing

100032

Peking Union Medical College Hospital, Beijing

100037

Fu Wai Hospital, Beijing

100038

Beijing Shijitan Hospital, Beijing

200032

Zhongshan Hospital affiliated with Fudan University, Shanghai

200433

Shanghai Pulmonary Hospital, Shanghai

410008

Xiangya Hospital Centre South University, Changsha

430022

Wuhan Asia Heart Hospital, Wuhan

510080

Guangdong General Hospital, Guangzhou

Sponsors
All Listed Sponsors
collaborator

CVie Therapeutics Co. Ltd.

INDUSTRY

lead

United Therapeutics

INDUSTRY